Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Twist Bioscience Corporation TWST

Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throu...


Recent & Breaking News (NDAQ:TWST)

Twist Bioscience Named in Inc.'s First Annual Best-Led Companies List

Business Wire November 2, 2021

Twist Bioscience to Report Fiscal 2021 Fourth Quarter and Full Year Financial Results on Monday, November 22, 2021

Business Wire November 1, 2021

Twist Bioscience Launches Exome 2.0 for Genomics Research

Business Wire October 20, 2021

Twist Bioscience and the Broad Institute Create Custom Whole Exome Target Enrichment Panel for Clinical Research

Business Wire October 13, 2021

Twist Bioscience Appoints Steffen Hellmold as Senior Vice President, Business Development, Data Storage

Business Wire October 12, 2021

CENTOGENE and Twist Bioscience to Develop Advanced Sequencing Tools to Make Genetic Testing Rapidly Accessible for More Patients With Rare Diseases

GlobeNewswire October 6, 2021

Twist Bioscience and CENTOGENE to Develop Advanced Sequencing Tools to Make Genetic Testing Rapidly Accessible for More Patients With Rare Diseases

Business Wire October 6, 2021

Twist Bioscience Expands Expert Custom Alliance Panel Offering

Business Wire October 5, 2021

Twist Bioscience Appoints Dennis Cho as Senior Vice President, General Counsel and Chief Ethics and Compliance Officer

Business Wire September 27, 2021

Twist Bioscience Internally-Discovered Single Domain Antibody TB202-3 Shows Potent Binding to Multiple Strains of SARS-CoV-2, Including Alpha, Beta, and Gamma Strains, in Preclinical Studies

Business Wire September 23, 2021

Twist Bioscience Collaborates with Deep Learning Experts deepCDR on Antibody Library Design

Business Wire September 23, 2021

Twist Bioscience Continues Commitment to Deliver Synthetic RNA Controls, now to Fight Delta Plus Variants of COVID-19

Business Wire September 14, 2021

Twist Bioscience Collaborates with Adicet Bio to Accelerate Discovery of Gamma Delta T Cell Cancer Therapeutics

Business Wire September 13, 2021

Twist Bioscience to Present at Baird 2021 Global Healthcare Conference

Business Wire September 8, 2021

SomaLogic and Twist Bioscience Corporation announce partnership to discover novel therapeutic targets and antibodies

GlobeNewswire August 18, 2021

Twist Bioscience to Present at UBS Genomics 2.0 and Medtech Innovations Summit

Business Wire August 10, 2021

Twist Bioscience Reports Third Quarter Fiscal 2021 Financial Results

Business Wire August 6, 2021

Twist Bioscience Appoints Drug Discovery Leader Melissa Starovasnik, Ph.D., to Board of Directors

Business Wire August 6, 2021

Twist Bioscience Incorporates MOLCURE AI Technology to Augment Therapeutic Antibody Discovery

Business Wire July 26, 2021

Twist Bioscience Now Shipping Synthetic RNA Positive Controls for Delta (B.1.617.2) SARS-CoV-2 Variant for Development of Accurate Diagnostic Tests

Business Wire July 22, 2021